EUVIMEDEUVIMED entdecken
Multizentrische Studie

Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization ( FILO )

Kamel Laribi iD, Stéphanie Poulain, Lise Willems, Fatiha Merabet, Charles Herbaux iD, Damien Roos-Weil iD, Inès Laribi de Materre, Xavier Roussel, Morgane Nudel, Sabine Tricot, Jehan Dupuis, Ronan Le Calloch iD und 2 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19409 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Kamel Laribi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Haematology Department, Le Mans Hospital, Le Mans, France. Hauptthemen laut MEDLINE: Bendamustine Hydrochloride, Waldenstrom Macroglobulinemia, Rituximab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The bendamustine–rituximab (BR) schedule is an efficient first‐line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who received this treatment confirmed a high response rate and good progression‐free (PFS) and overall survival (OS). With a median follow‐up of 76.1 months (95% confidence interval [CI] 69.9–80.6), 5‐year outcome is still excellent at 66.63% (95% CI 56.09–79.17) for PFS and 80.01% (95% CI 70.82–90.41) for OS. The rate of secondary cancers is 17.66% (IQR 7.99–27.64) at 66 months. Relapsed patients who received ibrutinib as second‐line clearly benefited from this schedule. This confirms current recommendations suggesting BR long‐term efficacy as first‐line option in WM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bendamustine HydrochlorideWaldenstrom MacroglobulinemiaRituximabAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedAged, 80 and overFranceFollow-Up StudiesTreatment Outcome

Stichwörter der Autor:innen

Waldenström macroglobulinaemiaantibody therapychemotherapy

Substanzen

Bendamustine HydrochlorideRituximab

Autor:innen und Institutionen

  • Haematology Department, Le Mans Hospital, Le Mans, France.
  • Cellular Haematology, Biology and Pathology Center, Lille Regional and University Hospital and INSERM UMR 1172, IRCL, Lille, France.
  • Haematology Clinic, Cochin Hospital, APHP, Paris, France.
  • Haematology and Oncology Clinic, André Mignot Hospital, Versailles Hospital, Versailles, France.
  • Haematology Clinic, Montpellier University Hospital, Montpellier, France.
  • Haematology Department, APHP, Sorbonne University, University Hospital La Pitié Salpêtrière-Charles Foix, Paris, France.

ORCID-Profile: Kamel Laribi, Charles Herbaux, Damien Roos-Weil, Ronan Le Calloch

Zitieren

APA

Laribi, K., Poulain, S., Willems, L., Merabet, F., Herbaux, C., Roos-Weil, D., Laribi de Materre, I., Roussel, X., Nudel, M., Tricot, S., Dupuis, J., Le Calloch, R., Bareau, B., & Leblond, V. (2024). Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization ( FILO ). British Journal of Haematology. https://doi.org/10.1111/bjh.19409

Vancouver

Laribi K, Poulain S, Willems L, Merabet F, Herbaux C, Roos-Weil D, et al. Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization ( FILO ). British Journal of Haematology. 2024. doi:10.1111/bjh.19409

BibTeX
@article{Laribi2024,
  author = {Laribi, Kamel and Poulain, Stéphanie and Willems, Lise and Merabet, Fatiha and Herbaux, Charles and Roos-Weil, Damien and Laribi de Materre, Inès and Roussel, Xavier and Nudel, Morgane and Tricot, Sabine and Dupuis, Jehan and Le Calloch, Ronan and Bareau, Benoit and Leblond, Véronique},
  title = {Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization ( FILO )},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19409}
}
Kostenlos starten →